NASDAQ:COEP Coeptis Therapeutics (COEP) Stock Price, News & Analysis $0.14 +0.00 (+1.72%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Coeptis Therapeutics Stock (NASDAQ:COEP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Coeptis Therapeutics alerts:Sign Up Key Stats Today's Range$0.14▼$0.1450-Day Range$0.14▼$0.2352-Week Range$0.13▼$0.87Volume72,919 shsAverage Volume361,385 shsMarket Capitalization$5.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewCoeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.Read More… Coeptis Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks8th Percentile Overall ScoreCOEP MarketRank™: Coeptis Therapeutics scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Coeptis Therapeutics.Read more about Coeptis Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Coeptis Therapeutics are expected to grow in the coming year, from ($0.26) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coeptis Therapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coeptis Therapeutics is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoeptis Therapeutics has a P/B Ratio of 7.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.93% of the float of Coeptis Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoeptis Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Coeptis Therapeutics has recently increased by 10.97%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCoeptis Therapeutics does not currently pay a dividend.Dividend GrowthCoeptis Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.93% of the float of Coeptis Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoeptis Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Coeptis Therapeutics has recently increased by 10.97%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Coeptis Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Coeptis Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Coeptis Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.25% of the stock of Coeptis Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.88% of the stock of Coeptis Therapeutics is held by institutions.Read more about Coeptis Therapeutics' insider trading history. Receive COEP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coeptis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address COEP Stock News HeadlinesCoeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis TechnologiesDecember 26 at 8:15 AM | prnewswire.comCoeptis Therapeutics Unveils New Technology Division: Coeptis TechnologiesDecember 12, 2024 | prnewswire.com[PDF] The Opportunity in GoldCommodities expert, Geof Smith, insists that the supercycle on gold is just getting warmed up. In fact, even though gold looks like this since he initially called a major bull run 11 months ago… He’s still predicting it will be the TOP trade of 2025. His free eBook explains why You see, the last time gold launched into a supercycle like this it surged 536% The time before that was over 1,000%... That’s why Geof released this urgent guide to help you. Most people think they’ve missed out, but he thinks we’re at the very beginning of what could be the largest gold rally of our lifetimes. But, believe it or not, Geof doesn’t think you should just buy and hold precious metals. He’ll share more about his approach inside the eBook and it might surprise you.December 26, 2024 | DTI (Ad)Coeptis Therapeutics to acquire NexGenAI Affiliates NetworkDecember 4, 2024 | markets.businessinsider.comCoeptis Therapeutics takes steps to acquire NexGenAI Affiliates NetworkDecember 3, 2024 | bizjournals.comCoeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other IndustriesDecember 3, 2024 | prnewswire.comCoeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical DevelopmentNovember 7, 2024 | prnewswire.comCoeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency UseOctober 24, 2024 | prnewswire.comSee More Headlines COEP Stock Analysis - Frequently Asked Questions How have COEP shares performed this year? Coeptis Therapeutics' stock was trading at $0.7839 at the start of the year. Since then, COEP shares have decreased by 81.9% and is now trading at $0.1420. View the best growth stocks for 2024 here. How were Coeptis Therapeutics' earnings last quarter? Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) issued its earnings results on Friday, August, 16th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. How do I buy shares of Coeptis Therapeutics? Shares of COEP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Coeptis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Coeptis Therapeutics investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), PayPal (PYPL), Tesla (TSLA), Meta Platforms (META), 3M (MMM) and PHX Minerals (PHX). Company Calendar Last Earnings8/16/2024Today12/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COEP CUSIPN/A CIK1759186 Webcoeptispharma.com Phone724-934-6467FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,094.50% Return on Assets-219.97% Debt Debt-to-Equity Ratio0.03 Current Ratio0.40 Quick Ratio0.40 Sales & Book Value Annual Sales$80,000.00 Price / Sales72.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book7.10Miscellaneous Outstanding Shares41,119,000Free Float31,148,000Market Cap$5.84 million OptionableNot Optionable Beta-0.90 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:COEP) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
